Acutus is finally making big moves to expand further. FDA has recently cleared its AcQCros Qx system, an expanded suite of left-heart access products. Since January NASDAQ: AFIB has been plunging from $3.92 to $0.5384 as of June 24.
After the recent clearance from FDA, the stock jumped 121% abruptly on millions of shares. Hopefully, AcQCros will contribute to increasing the revenue and beat the earnings estimates for Q3 2022.
The company will increase expenses to market the cleared product. Additionally, cutting costs and layoffs could lead to decreased losses. Q2 financial results would not be more positive than the upcoming Q3. Starting from July to September 2022 the revenue might significantly increase by pushing the earnings up.